FDA WARNING_LETTER - directmeds.com, Inc. dba DirectMeds - August 31, 2025

The FDA issued a warning letter to DirectMeds, located at 14572 S 790 W #A100, Bluffdale, UT, on September 9, 2025, following a review of their website in August 2025. The FDA identified that DirectMeds" website offers compounded drug products, including semaglutide and tirzepatide, with claims that are false or misleading under sections 502(a) and 502(bb) of the Federal Food, Drug, and Cosmetic Act (FDCA). These claims suggest that the compounded drugs are equivalent to FDA-approved products, which they are not, resulting in the products being misbranded and introduced into interstate commerce in violation of section 301(a) of the FDCA.

The FDA highlighted specific misleading claims on the website, such as compounded semaglutide being a cost-effective alternative to brand-name versions and containing the same active ingredients. The letter emphasizes that compounded drugs are not FDA-approved, and the claims imply a false equivalence to approved products.

DirectMeds is required to take immediate corrective actions, including ceasing the use of misleading language. They must respond within 15 working days to the Office of Compounding Quality and Compliance, detailing steps taken to address the violations and prevent recurrence. Failure to comply may result in legal actions, including product seizure and injunction. The letter serves as a formal notification of the FDA"s concerns and provides DirectMeds an opportunity to rectify the issues.